Cogent Biosciences, Inc. (COGT)
After hours:
Cogent Biosciences, Inc.
275 Wyman Street
3rd Floor
Waltham, MA 02451
United States
617 945 5576
https://www.cogentbio.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 164
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Andrew R. Robbins M.B.A. | President, CEO & Director | 1.06M | N/A | 1976 |
| Dr. John Edward Robinson Ph.D. | Chief Scientific Officer | 749.89k | N/A | 1975 |
| Dr. Jessica Sachs M.D. | Chief Medical Officer | 773.92k | N/A | 1975 |
| Mr. John L. Green C.A., CPA | CFO & Principal Accounting Officer | 763.99k | N/A | 1980 |
| Mr. Brad Barnett | Chief Technology Officer | N/A | N/A | N/A |
| Christi Waarich | Senior Director of Investor Relations | N/A | N/A | N/A |
| Mr. Evan D. Kearns J.D. | Chief Legal Officer & Corporate Secretary | N/A | N/A | 1980 |
| Ms. Erin Schellhammer | Chief People Officer | N/A | N/A | N/A |
| Mr. Dana R. Martin Pharm.D. | Senior Vice President of Medical Affairs | N/A | N/A | N/A |
| Brad Fell | Senior Vice President of Chemistry | N/A | N/A | N/A |
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Cogent Biosciences, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 8.
